Skip to main content
Login
Contact
Subscribe
Search form
Search
Mammoth Times
Click for weather forecast
Home
Forms
News
Obituaries
Sports/Outdoors
Classifieds
Place an Ad
Photos
Videos
Games
Mountain
Snow Report
Ski Report
Road Conditions
Entertainment
Local Guide
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Exact Sciences Cor
(NQ:
EXAS
)
142.61
USD
-11.32 (-7.35%)
Streaming Delayed Price
Updated: 1:12 PM EST, Jan 26, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Exact Sciences Cor
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology
January 13, 2021
Worldwide Exclusive License Provides Access to Targeted Digital Sequencing (TARDIS) Blood Biopsy Method for Use in Minimal Residual Disease Testing
From
PR Newswire
New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®
January 12, 2021
Cologuard's high specificity would help minimize risk and cost from unnecessary diagnostic procedures in this age group
From
PR Newswire
Should you invest in Exxon Mobil, Wells Fargo, General Motors, Etsy, or EXACT Sciences?
January 12, 2021
InvestorsObserver issues critical PriceWatch Alerts for XOM, WFC, GM, ETSY, and EXAS.
From
PR Newswire
Exact Sciences Announces Preliminary Fourth Quarter 2020 Results
January 10, 2021
- Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue of $98.5-99.5M
From
PR Newswire
Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening
January 05, 2021
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive").
From
PR Newswire
Exact Sciences to participate in J.P. Morgan Healthcare Conference
December 28, 2020
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast.
From
PR Newswire
Cognitive Assessment & Training in Healthcare Market Could Reach $45 Billion by 2026
December 23, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Cognitive Assessment & Training in Healthcare Market Could Reach $45 Billion by 2026
December 23, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice
December 11, 2020
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions in breast cancer patients with high clinical risk, including those with...
From
PR Newswire
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
December 09, 2020
Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial successfully defined the benefit of chemotherapy in...
From
PR Newswire
Exact Sciences to participate in December investor conference
November 23, 2020
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast.
From
PR Newswire
Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)
November 17, 2020
Consortium aims to make comprehensive genomic profiling accessible to advanced cancer patients in the U.S. to inform medical management and improve patient outcomes.
From
PR Newswire
Exact Sciences to participate in November investor conferences
November 02, 2020
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate by webcast.
From
PR Newswire
Thinking about buying stock in Apple, Titan Pharmaceuticals, Tupperware Brands, EXACT Sciences, or Roku?
October 28, 2020
InvestorsObserver issues critical PriceWatch Alerts for AAPL, TTNP, TUP, EXAS, and ROKU.
From
PR Newswire
Exact Sciences Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45
October 27, 2020
Cologuard® remains a recommended screening method in the draft
From
PR Newswire
Thinking about buying stock in Xilinx, General Electric, EXACT Sciences, Harley-Davidson, or American International?
October 27, 2020
InvestorsObserver issues critical PriceWatch Alerts for XLNX, GE, EXAS, HOG, and AIG.
From
PR Newswire
Exact Sciences Announces Entry into Agreements to Sell $869 Million of Common Stock in Registered Direct Offering
October 27, 2020
Exact Sciences Corporation (Nasdaq: EXAS) today announced the entry into agreements to sell an aggregate of 8,605,483 shares (the "Shares") of its common stock, par value $0.01 per share, in a...
From
PR Newswire
Exact Sciences Announces Third Quarter 2020 Results
October 27, 2020
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, compared to $218.8 million for the same period...
From
PR Newswire
Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening
October 27, 2020
Brings Together Cancer Screening R&D Pioneers to Transform the Future of Cancer Diagnostics and Impact Lives
From
PR Newswire
Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer
October 12, 2020
Comprehensive genomic profiling panel aids therapy selection decisions for a breadth of solid tumor types
From
PR Newswire
Exact Sciences schedules third quarter 2020 earnings call
October 09, 2020
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third quarter 2020 financial results after the close of the U.S. financial markets on October 29, 2020....
From
PR Newswire
Thinking about trading options or stock in Netflix, EXACT Sciences, Apple, American Airlines, or Purple Innovation?
October 07, 2020
InvestorsObserver issues critical PriceWatch Alerts for NFLX, EXAS, AAPL, AAL, and PRPL.
From
PR Newswire
Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement
October 07, 2020
Successful collaboration will continue to support Cologuard adoption through 2022
From
PR Newswire
Researchers Look for New Ways to Boost Diagnostic Capabilities
October 02, 2020
FinancialBuzz.com News Commentary
From
PR Newswire
Thinking about trading options or stock in Royal Caribbean Cruises, Caesars Entertainment, EXACT Sciences, Boeing, or AT&T?
September 25, 2020
InvestorsObserver issues critical PriceWatch Alerts for RCL, CZR, EXAS, BA, and T.
From
PR Newswire
Exact Sciences to participate in Cowen Liquid Biopsy Summit
September 17, 2020
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following event and invited investors to participate by webcast.
From
PR Newswire
Bullish Beta Stocks Showing Potential Of High Returns: $MPLX $EXAS $LEN
September 07, 2020
Tags
The Market Signal
From
The Market Signal
Diagnostic Methods Benefit from Rapidly Advancing Technologies
September 04, 2020
FinancialBuzz.com News Commentary
From
PR Newswire
Exact Sciences to participate in September investor conference
September 01, 2020
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast.
From
PR Newswire
Novel Cancer Treatments Arise as Scientists Search for Answers
August 25, 2020
FinancialBuzz.com News Commentary
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
X
Username
*
Password
*
Request new password